Acceleron Pharma (XLRN) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Join SI Premium – FREE
Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.77), $0.14 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.69 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Penguin Solutions (PENG) Tops Q4 EPS by 23c, Offers Guidance
- Helen of Troy (HELE) Tops Q2 EPS by 28c, Misses on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
